Cover Image

Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer

Since the US FDA-approval of the first immune checkpoint inhibitor, anticytotoxic T-lymphocyte antigen-4 monoclonal antibody ipilimumab, for metastatic melanoma on 28 March 2011, another six agents have been granted use among a multitude of tumors, including renal cell cancer, Hodgkin lymphoma, urot...

Full description

Saved in:
Bibliographic Details
Main Authors: Mavratzas, Athanasios (Author) , Seitz, Julia (Author) , Smetanay, Katharina (Author) , Schneeweiss, Andreas (Author) , Jäger, Dirk (Author) , Fremd, Carlo (Author)
Format: Article (Journal)
Language:English
Published: 2020
In: Future oncology
Year: 2019, Volume: 16, Issue: 3, Pages: 4439-4453
ISSN:1744-8301
DOI:10.2217/fon-2019-0468
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.2217/fon-2019-0468
Verlag, lizenzpflichtig, Volltext: https://www.futuremedicine.com/doi/full/10.2217/fon-2019-0468
Get full text
Author Notes:Athanasios Mavratzas, Julia Seitz, Katharina Smetanay, Andreas Schneeweiss, Dirk Jäger & Carlo Fremd
Description
Summary:Since the US FDA-approval of the first immune checkpoint inhibitor, anticytotoxic T-lymphocyte antigen-4 monoclonal antibody ipilimumab, for metastatic melanoma on 28 March 2011, another six agents have been granted use among a multitude of tumors, including renal cell cancer, Hodgkin lymphoma, urothelial carcinoma and non-small-cell lung cancer. The first anti-programmed cell death ligand-1 monoclonal antibody to receive the FDA approval, atezolizumab (Tecentriq®), has yielded promising results among international Phase III trials in triple-negative breast cancer and small-cell lung cancer, expanding the field of cancer immunotherapies. Herein, we review the pharmacodynamic and pharmacokinetic properties of atezolizumab, its safety and efficacy data from early clinical trials and summarize data from Phase III IMpassion130 trial, prompting FDA and EMA approval of atezolizumab in metastatic triple-negative breast cancer. Finally, implications for clinical use and ongoing research will be briefly discussed.
Item Description:Published online 12 Dec 2019
Gesehen am 19.06.2020
Physical Description:Online Resource
ISSN:1744-8301
DOI:10.2217/fon-2019-0468

Similar Items